Structure Therapeutics price target lowered to $87 from $91 at Citizens JMP

Citizens JMP lowered the firm’s price target on Structure Therapeutics (GPCR) to $87 from $91 and keeps an Outperform rating on the shares. Structure Therapeutics has completed enrollment in its Phase 2b ACCESS trials of aleniglipron with data coming from both before the end of 2025, the analyst tells investors in a research note. The ACCESS data is the key catalyst for Structure shares but before then, Phase 3 data from Eli Lilly’s (LLY) orforglipron may put pressure on the stock and provide an attractive opportunity ahead of Structure’s data, the firm says.